Could Biologically Enhancing Our Morality Save Our Species?

Could Biologically Enhancing Our Morality Save Our Species?

A human head pictured with a red heart in the place of a brain.

(© blacksalmon/Fotolia)


Keep Reading Keep Reading
Julian Savulescu
Professor Julian Savulescu has held the Uehiro Chair in Practical Ethics at the University of Oxford since 2002. He has degrees in medicine, neuroscience and bioethics. He directs the Oxford Uehiro Centre for Practical Ethics within the Faculty of Philosophy, and co-directs the interdisciplinary Wellcome Centre for Ethics and Humanities in collaboration with Public Health, Psychiatry and History. In 2017, he joined the Murdoch Children’s Research Institute, spending four months per year as Visiting Professorial Fellow in Biomedical Ethics where he is working to establish a program in biomedical ethics, and Melbourne University as Distinguished International Visiting Professor in Law. He is Editor of the Journal of Medical Ethics and received an honorary doctorate from the University of Bucharest in 2014. (Photo credit: Murray Bransgrove)
Hidden figures: Five black women that changed science forever

Dr. May Edward Chinn, Kizzmekia Corbett, PhD., and Alice Ball, among others, have been behind some of the most important scientific work of the last century.


Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.